Drug Development

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Articles

Choosing the right container and container closure system is crucial for ensuring product quality, safety, and efficacy of a biologic formulation.

Container Selection for Biologic Formulations

Headspace moisture analysis is a rapid non-destructive analytical method that may potentially address the limitations of traditional methods used for residual moisture determination.

Headspace Moisture Analysis for Determination of Residual Moisture Content in Lyophilized Pharmaceutical Products

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Global outbreaks energize vaccine R&D and drive production modernization.

Vaccine Development Faces  Urgency and Challenges

Agnes Shanley is senior editor of Pharmaceutical Technology.

At DCAT's annual meeting, Bill Downey, president of the market research firm High Tech Business Decisions, summarized results from its latest survey on biopharmaceutical outsourcing.

Biopharmaceutical Outsourcing Continues to Grow

Industry is joining with academia and global health leaders to examine new approaches to biotech manufacturing.

Biotech Manufacturers Explore Global Access and Supply Chain Hurdles

Novo Nordisk broke ground on a facility in Clayton, NC, to manufacture APIs for GLP-1 and insulin medicines.

Novo Nordisk Builds Manufacturing Facility in North Carolina

A team of Bristol-Myers Squibb scientists will work in a new laboratory at the National Institute of Bioprocessing Research and Training facility in Dublin, Ireland.

Bristol-Myers Squibb Collaborates with Bioprocessing Institute in Ireland

Collaboration will provide for unified development and manufacture of antibody drug conjugates.

CMC Biologics and IDT Biologika Collaborate on ADC Manufacturing

The Human Vaccines Project brings together academic research centers, industrial partners, nonprofit organizations, and governments to address the primary scientific barriers to developing new vaccines and immunotherapies.

Pfizer Joins the Human Vaccines Project

During a clinical trial of 48 participants, 100% of those that received the TV003 vaccine were protected from infection.

Formulation and Drug Delivery